Across TCGA pan-cancer cohorts, PCGF3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PCGF3 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PCGF3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PCGF3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ESCA, UCEC, and SKCM are the cancer types where PCGF3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.164	0.702	.001	33	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.561	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PCGF3 tumor-vs-normal RNA expression · all PCGF3 data types